Page 326 - Haematologica Vol. 109 - July 2024

LETTER TO THE EDITOR
Bristol Myers Squibb, GlaxoSmithKline, Janssen, and Lilly. Eirini K discloses research support/principal investigator from Amgen, Janssen, Takeda, Sanofi, Karyopharm, GSK, Abbvie, Pfizer and GSK; honoraria from Amgen, Genesis-Pharma, Janssen, Takeda, Integris- Pharma, Sanofi, Abbvie and GSK; and scientific advisory board from Amgen, Janssen, Takeda and Sandoz. FG discloses honoraria/advisory board from Janseen, BMS, Takeda, Amgen, Sanofi, Roche, Abbvie and GSK; and advisory board from Pfizer and Oncopeptides. AL discloses honoraria and scientific advisory board from Janssen-Cilag, BMS, Amgen, Takeda, Oncopeptides, GSK, Sanofi and Karyopharm. XL has received honoraria from Janssen, Takeda, Sanofi, Pfizer, Roche, BMS, GSK, Iteos, Abbvie, Regeneron and Amgen. PR-O discloses receiving honoraria from consulting activities from BMS, Janssen, Sanofi, Kite Pharma, Abbvie, Oncopeptides, Takeda, Pfizer, Roche, Pfizer and GSK, and from lectures from BMS, Janssen, Sanofi, GSK, Amgen, Regeneron and Takeda. FS has received honoraria derived from lectures and participation in boards from Abbvie, GSK, Celgene, Takeda, Janssen, Oncopeptides, Sanofi, BMS, Amgen, BMS, Novartis,
References
1. Dimopoulos MA, Moreau P, Terpos E, et al. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up(†). Ann Oncol. 2021;32(3):309-322.
2. Gandhi UH, Cornell RF, Lakshman A, et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. 2019;33(9):2266-2275.
3. Lee L, Bounds D, Paterson J, et al. Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma. Br J Haematol. 2016;174(6):911-922.
4. O’Connor BP, Raman VS, Erickson LD, et al. BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp Med. 2004;199(1):91-98.
5. Nath K, Costa BA, Mailankody S. GPRC5D as a novel immunotherapeutic target in multiple myeloma. Nat Rev Clin Oncol. 2023;20(5):281-282.
6. Montes de Oca R, Alavi AS, Vitali N, et al. Belantamab mafodotin (GSK2857916) drives immunogenic cell death and immune- mediated antitumor responses in vivo. Mol Cancer Ther. 2021;20(10):1941-1955.
7. Tai YT, Anderson KC. Targeting B-cell maturation antigen in multiple myeloma. Immunotherapy. 2015;7(11):1187-1199.
8. Tai YT, Mayes PA, Acharya C, et al. Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood. 2014;123(20):3128-3138.
9. Nooka AK, Cohen AD, Lee HC, et al. Single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: final analysis of the DREAMM-2 trial. Cancer. 2023;129(23):3746-3760.
10. Dimopoulos MA, Hungria VTM, Radinoff A, et al. Efficacy and safety of single-agent belantamab mafodotin versus
SkyliteDX, Pfizer and Daiki-Sankyo. MC received honoraria from Janssen, Celgene/Bristol Myers Squibb, Sanofi, Takeda, Amgen, AbbVie, Adaptive, GSK, Pfizer and Menarini/Stemline; and served on a speakers bureau for Janssen, Celgene/Bristol Myers Squibb and Sanofi. MAD has received honoraria from participation in advisory boards and satellite symposia from Amgen, Sanofi, Regeneron, Menarini, Takeda, GSK, BMS, Janssen and Beigene.
Contributions
All authors contributed to writing the letter. All authors critically revised and approved the final version of the letter and agree with presented format.
Data-sharing statement
The data that support this manuscript are not openly available because they have not been generated by the auhtors but can be available from the corresponding author of each study, here referenced, and after a reasonable request.
pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study. Lancet Haematol. 2023;10(10):e801-e812.
11. Mateos M-V, Beksac M, Dimopoulos M, et al. Results from the randomized, open-label phase 3 CANOVA study of venetoclax- dexamethasone versus pomalidomide- dexamethasone in patients with t(11;14)-positive relapsed/refractory multiple myeloma. Presented at International Myeloma Society Annual Meeting; September 27-30, 2023; Athens, Greece. Abstract OA-52.
12. Schjesvold FH, Dimopoulos MA, Delimpasi S, et al. Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study. Lancet Haematol. 2022;9(2):e98-e110.
13. Richardson PG, Oriol A, Larocca A, et al. Melflufen and dexamethasone in heavily pretreated relapsed and refractory multiple myeloma. J Clin Oncol. 2021;39(7):757-767.
14. de la Rubia J, Alonso R, Clavero ME, et al. Belantamab mafodotin in patients with relapsed/refractory multiple myeloma: results of the compassionate use or the expanded access program in Spain. Cancers (Basel). 2023;15(11):2964.
15. Ntanasis-Stathopoulos I, Malandrakis P, Fotiou D, et al. Real- world effectiveness and safety of belantamab mafodotin monotherapy in triple-class refractory multiple myeloma. Int J Mol Sci. 2023;24(14):11829.
16. Markouli M, Ullah F, Unlu S, et al. Toxicity profile of chimeric antigen receptor T-cell and bispecific antibody therapies in multiple myeloma: pathogenesis, prevention and management. Curr Oncol. 2023;30(7):6330-6352.
Haematologica | 109 July 2024
2340